Anakinra for colchicine‐resistant familial Mediterranean fever: a randomized, double‐blind, placebo‐controlled trial
I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - Wiley Online Library
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial
I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - Wiley Online Library
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
[引用][C] Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial
I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - cir.nii.ac.jp
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind,
Placebo‐Controlled Trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Placebo‐Controlled Trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial
I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - infona.pl
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …
Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial
I Ben-Zvi, O Kukuy, E Giat, E Pras, O Feld, S Kivity… - 2017 - pubmed.ncbi.nlm.nih.gov
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10-
20% of patients. In a number of patient series, treatment with anakinra, an interleukin-1 …
20% of patients. In a number of patient series, treatment with anakinra, an interleukin-1 …
Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.
I Ben-Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - europepmc.org
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10-
20% of patients. In a number of patient series, treatment with anakinra, an interleukin-1 …
20% of patients. In a number of patient series, treatment with anakinra, an interleukin-1 …